QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
Title of each class | Trading symbol | Name of each exchange on which registered | ||
☒ | Accelerated filer | ☐ | ||||
Non-accelerated filer | ☐ | Smaller reporting company | ||||
Emerging growth company |
Class | Outstanding as of January 7, 2020 | |
Common Stock, par value $.01 |
Page | ||
Item 1. | ||
Item 2. | ||
Item 3. | ||
Item 4. | ||
Item 1. | ||
Item 1A. | ||
Item 2. | ||
Item 3. | ||
Item 4. | ||
Item 5. | ||
Item 6. |
Three Months Ended | Six Months Ended | |||||||||||||||
Nov 30, 2019 | Nov 30, 2018 | Nov 30, 2019 | Nov 30, 2018 | |||||||||||||
Net sales | $ | $ | $ | $ | ||||||||||||
Cost of sales (exclusive of intangible amortization) | ||||||||||||||||
Gross profit | ||||||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | ||||||||||||||||
Sales and marketing | ||||||||||||||||
General and administrative | ||||||||||||||||
Amortization of intangibles | ||||||||||||||||
Change in fair value of contingent consideration | ( | ) | ||||||||||||||
Acquisition, restructuring and other items, net | ||||||||||||||||
Total operating expenses | ||||||||||||||||
Operating loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Other (expenses) income: | ||||||||||||||||
Interest expense, net | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Other income (expense), net | ||||||||||||||||
Total other income (expense), net | ( | ) | ( | ) | ( | ) | ||||||||||
Loss from continuing operations before income tax benefit | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Income tax benefit | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Net loss from continuing operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Income from discontinued operations, net of income tax | ||||||||||||||||
Net income (loss) | $ | ( | ) | $ | $ | ( | ) | $ | ||||||||
Loss per share - continuing operations | ||||||||||||||||
Basic | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
Diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
Income per share - discontinued operations | ||||||||||||||||
Basic | $ | $ | $ | $ | ||||||||||||
Diluted | $ | $ | $ | $ | ||||||||||||
Income (loss) per share | ||||||||||||||||
Basic | $ | ( | ) | $ | $ | ( | ) | $ | ||||||||
Diluted | $ | ( | ) | $ | $ | ( | ) | $ | ||||||||
Weighted average shares outstanding | ||||||||||||||||
Basic | ||||||||||||||||
Diluted |
Three Months Ended | Six Months Ended | |||||||||||||||
Nov 30, 2019 | Nov 30, 2018 | Nov 30, 2019 | Nov 30, 2018 | |||||||||||||
Net income (loss) | $ | ( | ) | $ | $ | ( | ) | $ | ||||||||
Other comprehensive income (loss), before tax: | ||||||||||||||||
Unrealized gain on marketable securities | ||||||||||||||||
Foreign currency translation | ( | ) | ( | ) | ||||||||||||
Other comprehensive income (loss), before tax | ( | ) | ( | ) | ||||||||||||
Income tax expense related to items of other comprehensive income | ||||||||||||||||
Other comprehensive income (loss), net of tax | ( | ) | ( | ) | ||||||||||||
Total comprehensive income (loss), net of tax | $ | ( | ) | $ | $ | ( | ) | $ |
Nov 30, 2019 | May 31, 2019 | ||||||
Assets | |||||||
Current assets | |||||||
Cash and cash equivalents | $ | $ | |||||
Accounts receivable, net of allowances of $2,068 and $1,906 respectively | |||||||
Inventories | |||||||
Prepaid expenses and other | |||||||
Total current assets | |||||||
Property, plant and equipment, net | |||||||
Other assets | |||||||
Intangible assets, net | |||||||
Goodwill | |||||||
Total assets | $ | $ | |||||
Liabilities and stockholders' equity | |||||||
Current liabilities | |||||||
Accounts payable | $ | $ | |||||
Accrued liabilities | |||||||
Current portion of long-term debt | |||||||
Current portion of contingent consideration | |||||||
Other current liabilities | |||||||
Total current liabilities | |||||||
Long-term debt, net of current portion | |||||||
Contingent consideration, net of current portion | |||||||
Deferred income taxes | |||||||
Other long-term liabilities | |||||||
Total liabilities | |||||||
Commitments and contingencies (Note 15) | |||||||
Stockholders' equity | |||||||
Preferred stock, par value $.01 per share, 5,000,000 shares authorized; no shares issued and outstanding | |||||||
Common stock, par value $.01 per share, 75,000,000 shares authorized; 38,363,926 and 37,984,382 shares issued and 37,993,926 and 37,614,382 shares outstanding at November 30, 2019 and May 31, 2019, respectively | |||||||
Additional paid-in capital | |||||||
Retained earnings | |||||||
Treasury stock, 370,000 shares at November 30, 2019 and May 31, 2019, respectively | ( | ) | ( | ) | |||
Accumulated other comprehensive loss | ( | ) | ( | ) | |||
Total Stockholders’ Equity | |||||||
Total Liabilities and Stockholders' Equity | $ | $ |
Six Months Ended | |||||||
Nov 30, 2019 | Nov 30, 2018 | ||||||
Cash flows from operating activities: | |||||||
Net income (loss) | $ | ( | ) | $ | |||
Adjustments to reconcile net loss to net cash provided by operating activities: | |||||||
Depreciation and amortization | |||||||
Non-cash lease expense | — | ||||||
Stock based compensation | |||||||
Change in fair value of contingent consideration | ( | ) | |||||
Deferred income taxes | ( | ) | |||||
Change in accounts receivable allowances | ( | ) | |||||
Fixed and intangible asset impairments and disposals | |||||||
Write-off of other assets | |||||||
Other | ( | ) | ( | ) | |||
Changes in operating assets and liabilities: | |||||||
Accounts receivable | ( | ) | |||||
Inventories | ( | ) | ( | ) | |||
Prepaid expenses and other | ( | ) | ( | ) | |||
Accounts payable, accrued and other liabilities | ( | ) | ( | ) | |||
Net cash provided by (used in) operating activities | ( | ) | |||||
Cash flows from investing activities: | |||||||
Additions to property, plant and equipment | ( | ) | ( | ) | |||
Acquisition of intangibles | ( | ) | |||||
Cash paid for acquisitions | ( | ) | ( | ) | |||
Net cash used in investing activities | ( | ) | ( | ) | |||
Cash flows from financing activities: | |||||||
Proceeds from issuance of and borrowings on long-term debt | |||||||
Repayment of long-term debt | ( | ) | ( | ) | |||
Deferred financing costs on long-term debt | ( | ) | |||||
Payment of acquisition related contingent consideration | ( | ) | ( | ) | |||
Proceeds (outlays) from exercise of stock options and employee stock purchase plan | ( | ) | |||||
Net cash provided by (used in) financing activities | ( | ) | |||||
Effect of exchange rate changes on cash and cash equivalents | ( | ) | |||||
Decrease in cash and cash equivalents | ( | ) | ( | ) | |||
Cash and cash equivalents at beginning of period | |||||||
Cash and cash equivalents at end of period | $ | $ | |||||
Supplemental disclosure of non-cash investing and financing activities: | |||||||
Accrual for capital expenditures incurred during the period | $ | $ | ( | ) | |||
Fair value of contingent consideration for acquisitions | |||||||
Fair value of acquisition consideration included in other long-term liabilities |
Common Stock | Additional paid in capital | Retained earnings | Accumulated other comprehensive loss | Treasury Stock | |||||||||||||||||||||||||
Shares | Amount | Shares | Amount | Total | |||||||||||||||||||||||||
Balance at May 31, 2019 | $ | $ | $ | $ | ( | ) | ( | ) | $ | ( | ) | $ | |||||||||||||||||
Net loss | ( | ) | ( | ) | |||||||||||||||||||||||||
Exercise of stock options | |||||||||||||||||||||||||||||
Issuance/Cancellation of restricted stock units | ( | ) | ( | ) | |||||||||||||||||||||||||
Purchases of common stock under ESPP | |||||||||||||||||||||||||||||
Stock-based compensation | |||||||||||||||||||||||||||||
Other comprehensive loss, net of tax | ( | ) | ( | ) | |||||||||||||||||||||||||
Balance at August 31, 2019 | $ | $ | $ | $ | ( | ) | ( | ) | $ | ( | ) | $ | |||||||||||||||||
Net loss | ( | ) | ( | ) | |||||||||||||||||||||||||
Issuance/Cancellation of restricted stock units | |||||||||||||||||||||||||||||
Stock-based compensation | 2,242 | ||||||||||||||||||||||||||||
Other comprehensive loss, net of tax | |||||||||||||||||||||||||||||
Balance at November 30, 2019 | $ | $ | $ | $ | ( | ) | ( | ) | $ | ( | ) | $ |
Common Stock | Additional paid in capital | Retained earnings | Accumulated other comprehensive loss | Treasury Stock | |||||||||||||||||||||||||
Shares | Amount | Shares | Amount | Total | |||||||||||||||||||||||||
Balance at May 31, 2018 | $ | $ | $ | $ | ( | ) | ( | ) | $ | ( | ) | $ | |||||||||||||||||
Net loss | ( | ) | ( | ) | |||||||||||||||||||||||||
Exercise of stock options | |||||||||||||||||||||||||||||
Issuance/Cancellation of restricted stock units | ( | ) | ( | ) | |||||||||||||||||||||||||
Issuance/Cancellation of performance share units | |||||||||||||||||||||||||||||
Purchases of common stock under ESPP | |||||||||||||||||||||||||||||
Stock-based compensation | |||||||||||||||||||||||||||||
Other comprehensive loss, net of tax | ( | ) | ( | ) | |||||||||||||||||||||||||
Balance at August 31, 2018 | $ | $ | $ | $ | ( | ) | ( | ) | $ | ( | ) | $ | |||||||||||||||||
Net income | |||||||||||||||||||||||||||||
Exercise of stock options | |||||||||||||||||||||||||||||
Issuance/Cancellation of restricted stock units | |||||||||||||||||||||||||||||
Stock-based compensation | |||||||||||||||||||||||||||||
Other comprehensive loss, net of tax | ( | ) | ( | ) | |||||||||||||||||||||||||
Balance at November 30, 2018 | $ | $ | $ | $ | ( | ) | ( | ) | $ | ( | ) | $ |
(in thousands) | Oct 2, 2019 | ||
Accounts receivable | $ | ||
Inventory | |||
Prepaid and other current assets | |||
Long-term deposits | |||
Property, plant and equipment | |||
Intangible assets: | |||
Product technology | |||
Goodwill | |||
Total assets acquired | $ | ||
Liabilities assumed | |||
Accounts payable | $ | ||
Other current liabilities | |||
Deferred tax liabilities | |||
Total liabilities assumed | $ | ||
Net assets acquired | $ |
(in thousands) | Final allocation | ||
Accounts receivable | $ | ||
Inventory | |||
Prepaid and other current assets | |||
Property, plant and equipment | |||
Intangible assets: | |||
RadiaDyne trademark | |||
OARtrac trademark | |||
RadiaDyne legacy product technology | |||
OARtrac product technology | |||
RadiaDyne customer relationships | |||
Goodwill | |||
Total assets acquired | $ | ||
Liabilities assumed | |||
Accounts payable | $ | ||
Accrued expenses | |||
Total liabilities assumed | $ | ||
Net assets acquired | $ |
(in thousands) | Final allocation | ||
Inventory | $ | ||
Property, plant and equipment | |||
Intangible assets: | |||
BioSentry trademark | |||
BioSentry product technology | |||
Customer relationships | |||
Goodwill | |||
Net assets acquired | $ |
Three Months Ended | Six Months Ended | ||||||
(in thousands) | Nov 30, 2018 | Nov 30, 2018 | |||||
Net sales | $ | $ | |||||
Cost of sales (exclusive of amortization) | |||||||
Gross profit | |||||||
Operating expenses | |||||||
Research and development | |||||||
Sales and marketing | |||||||
General and administrative | |||||||
Amortization of intangibles | |||||||
Total operating expenses | |||||||
Operating income | |||||||
Income from discontinued operations before income taxes | |||||||
Income tax expense | |||||||
Income from discontinued operations | $ | $ |
Six Months Ended | |||
(in thousands) | Nov 30, 2018 | ||
Net cash provided by operating activities | $ | ||
Net cash provided by investing activities |
Three months ended Nov 30, 2019 | Three months Ended Nov 30, 2018 | ||||||||||||||||||||||
(in thousands) | United States | International | Total | United States | International | Total | |||||||||||||||||
Net sales | |||||||||||||||||||||||
Vascular Interventions & Therapies | $ | $ | $ | $ | $ | $ | |||||||||||||||||
Vascular Access | $ | ||||||||||||||||||||||
Oncology | $ | ||||||||||||||||||||||
Total | $ | $ | $ | $ | $ | $ |
Six months ended Nov 30, 2019 | Six months Ended Nov 30, 2018 | ||||||||||||||||||||||
(in thousands) | United States | International | Total | United States | International | Total | |||||||||||||||||
Net sales | |||||||||||||||||||||||
Vascular Interventions & Therapies | $ | $ | $ | $ | $ | $ | |||||||||||||||||
Vascular Access | |||||||||||||||||||||||
Oncology | |||||||||||||||||||||||
Total | $ | $ | $ | $ | $ | $ |
(in thousands) | Nov 30, 2019 | May 31, 2019 | |||||
Receivables | $ | $ | |||||
Contract assets | $ | $ | |||||
Contract liabilities | $ | $ |
(in thousands) | Nov 30, 2019 | May 31, 2019 | |||||
Raw materials | $ | $ | |||||
Work in process | |||||||
Finished goods | |||||||
Inventories | $ | $ |
(in thousands) | |||
Goodwill balance at May 31, 2019 | $ | ||
Additions for Eximo acquisition (Note 2) | |||
Goodwill balance at November 30, 2019 | $ |
Nov 30, 2019 | |||||||||||
(in thousands) | Gross carrying value | Accumulated amortization | Net carrying value | ||||||||
Product technologies | $ | $ | ( | ) | $ | ||||||
Customer relationships | ( | ) | |||||||||
Trademarks | ( | ) | |||||||||
Licenses | ( | ) | |||||||||
$ | $ | ( | ) | $ |
May 31, 2019 | |||||||||||
(in thousands) | Gross carrying value | Accumulated amortization | Net carrying value | ||||||||
Product technologies | $ | $ | ( | ) | $ | ||||||
Customer relationships | ( | ) | |||||||||
Trademarks | ( | ) | |||||||||
Licenses | ( | ) | |||||||||
$ | $ | ( | ) | $ |
(in thousands) | |||
Remainder of 2020 | $ | ||
2021 | |||
2022 | |||
2023 | |||
2024 | |||
2025 and thereafter | |||
$ |
(in thousands) | Nov 30, 2019 | May 31, 2019 | |||||
Payroll and related expenses | $ | $ | |||||
Royalties | |||||||
Accrued severance | |||||||
Sales and franchise taxes | |||||||
Outside services | |||||||
Litigation matters | |||||||
Indemnification holdback | |||||||
Other | |||||||
$ | $ |
• | maximum leverage ratio of consolidated total indebtedness* to consolidated EBITDA* of not greater than |
• | fixed charge coverage ratio of consolidated EBITDA minus consolidated capital expenditures to consolidated interest expense paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than |
Three Months Ended | Six Months Ended | ||||||||||
(in thousands) | Nov 30, 2019 | Nov 30, 2018 | Nov 30, 2019 | Nov 30, 2018 | |||||||
Basic | |||||||||||
Effect of dilutive securities | |||||||||||
Diluted | |||||||||||
Securities excluded as their inclusion would be anti-dilutive |
Three Months Ended | Six months ended | ||||||||||||||
(in thousands) | Nov 30, 2019 | Nov 30, 2018 | Nov 30, 2019 | Nov 30, 2018 | |||||||||||
Net sales | |||||||||||||||
Vascular Interventions & Therapies | $ | $ | $ | $ | |||||||||||
Vascular Access | |||||||||||||||
Oncology | |||||||||||||||
Total | $ | $ | $ | $ |
Three Months Ended | Six months ended | ||||||||||||||
(in thousands) | Nov 30, 2019 | Nov 30, 2018 | Nov 30, 2019 | Nov 30, 2018 | |||||||||||
Net sales | |||||||||||||||
United States | $ | $ | $ | $ | |||||||||||
International | |||||||||||||||
Total | $ | $ | $ | $ |
• | Level 1 - Inputs to the valuation methodology are quoted market prices for identical assets or liabilities. |
• | Level 2 - Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs. |
• | Level 3 - Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk. |
Fair Value Measurements using inputs considered as: | Fair Value at Nov 30, 2019 | ||||||||||||||
(in thousands) | Level 1 | Level 2 | Level 3 | ||||||||||||
Financial Liabilities | |||||||||||||||
Contingent consideration for acquisition earn outs | $ | $ | $ | $ | |||||||||||
Total Financial Liabilities | $ | $ | $ | $ | |||||||||||
Fair Value Measurements using inputs considered as: | Fair Value at May 31, 2019 | ||||||||||||||
(in thousands) | Level 1 | Level 2 | Level 3 | ||||||||||||
Financial Liabilities | |||||||||||||||
Contingent consideration for acquisition earn outs | $ | $ | $ | $ | |||||||||||
Total Financial Liabilities | $ | $ | $ | $ |
Three Months Ended Nov 30, 2019 | |||
(in thousands) | Fair Value Measurements Using Significant Unobservable Inputs (Level 3) | ||
Balance, August 31, 2019 | $ | ||
Total gains or losses (realized/unrealized): | |||
Contingent consideration liability recorded as the result of the acquisitions (Note 2) | |||
Change in present value of contingent consideration (1) | |||
Balance, November 30, 2019 | $ |
Six Months Ended Nov 30, 2019 | |||
(in thousands) | Fair Value Measurements Using Significant Unobservable Inputs (Level 3) | ||
Balance, May 31, 2019 | $ | ||
Total gains or losses (realized/unrealized): | |||
Contingent consideration liability recorded as the result of the acquisitions (Note 2) | |||
Change in present value of contingent consideration (1) | ( | ) | |
Contingent consideration payments | ( | ) | |
Balance, November 30, 2019 | $ |
(in thousands) | Fair Value | Valuation Technique | Unobservable Input | Range | |||||
Revenue based payments | $ | Discounted cash flow | Discount rate | 4% - 5% | |||||
Probability of payment | 66% - 100% | ||||||||
Projected fiscal year of payment | 2023 - 2029 | ||||||||
Technical milestones | $ | Estimated probability | Estimated probability | ||||||
Projected year of payment | 2020 - 2022 | ||||||||
Total | $ |
(in thousands) | Balance Sheet Location | Nov 30, 2019 | |||
Assets | |||||
Operating lease ROU asset | Other assets | $ | |||
Liabilities | |||||
Current operating lease liabilities | Other current liabilities | ||||
Non-current operating lease liabilities | Other long-term liabilities | ||||
Total lease liabilities | $ |
Nov 30, 2019 | ||
Weighted average remaining term (in years) | ||
Weighted average discount rate | % |
(in thousands) | Nov 30, 2019 | ||
Remainder of 2020 | $ | ||
2021 | |||
2022 | |||
2023 | |||
2024 | |||
2025 and thereafter | |||
Total lease payments | $ | ||
Less: Imputed Interest | |||
Total lease obligations | $ | ||
Less: Current portion of lease obligations | |||
Long-term lease obligations | $ |
(in thousands) | Three Months Ended | Six Months Ended | |||||
Cost of sales | $ | $ | |||||
Research and development | |||||||
Sales and marketing | |||||||
General and administrative | |||||||
$ | $ |
(in thousands) | May 31, 2019 | ||
2020 | $ | ||
2021 | |||
2022 | |||
2023 | |||
2024 and thereafter | |||
Total lease payments | $ |
(in thousands) | Nov 30, 2019 | ||
Cash paid for amounts included in the measurement of lease liabilities | |||
Operating cash flows from operating leases | $ | ||
ROU assets obtained in exchange for lease liabilities | |||
Operating leases |
Three months ended | Six months ended | ||||||||||||||
(in thousands) | Nov 30, 2019 | Nov 30, 2018 | Nov 30, 2019 | Nov 30, 2018 | |||||||||||
Legal (1) | $ | $ | $ | $ | |||||||||||
Mergers and acquisitions (2) | |||||||||||||||
Transition service agreement (3) | ( | ) | ( | ) | |||||||||||
Divestiture (4) | |||||||||||||||
Restructuring | |||||||||||||||
Other | |||||||||||||||
Total | $ | $ | $ | $ |
Three months ended Nov 30, 2019 | |||
(in thousands) | Foreign currency translation loss | ||
Balance at August 31, 2019 | $ | ( | ) |
Other comprehensive income before reclassifications, net of tax | |||
Amounts reclassified from accumulated other comprehensive loss | |||
Net other comprehensive loss | $ | ||
Balance at November 30, 2019 | $ | ( | ) |
Six months ended Nov 30, 2019 | |||
(in thousands) | Foreign currency translation loss | ||
Balance at May 31, 2019 | $ | ( | ) |
Other comprehensive income before reclassifications, net of tax | |||
Amounts reclassified from accumulated other comprehensive loss | |||
Net other comprehensive loss | $ | ||
Balance at November 30, 2019 | $ | ( | ) |
Recently Issued Accounting Pronouncements - Adopted | |||
Standard | Description | Date Adopted | Effect on the Consolidated Financial Statements |
ASU 2016-02, Leases (Topic 842) | This ASU increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and liabilities. | June 1, 2019 | Refer to Note 14, Leases, for the required disclosures related to adopting this standard. |
Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted | |||
Standard | Description | Effective Date | Effect on the Consolidated Financial Statements |
ASU 2018-13, Fair Value Measurement (Topic 820) | This ASU removes, modifies and adds various disclosure requirements related to fair value disclosures. Disclosures related to transfers between fair value hierarchy levels will be removed and further detail around changes in unrealized gains and losses for the period and unobservable inputs used in determining level 3 fair value measurements will be added, among other changes. | June 1, 2020 | The Company is currently assessing the impact of this standard on the consolidated financial statements. |
ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments | This ASU replaces the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. | June 1, 2020 | The Company is currently assessing the impact of this standard on the consolidated financial statements. |
Item 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations. |
• | Revenue was consistent with the prior year quarter to date |
• | Gross margin increased 140 bps to 59.3% |
• | Operating loss increased by $0.9 million to $3.4 million |
• | Loss per share from continuing operations improved by $0.03 to a loss of $0.07 |
• | Revenue increased by 1.6% to $136.0 million |
• | Gross margin increased 150 bps to 58.6% |
• | Operating loss decreased by $4.4 million to $4.3 million |
• | Loss per share from continuing operations improved by $0.14 to a loss of $0.11 |
Three months ended | |||||||||
(in thousands) | Nov 30, 2019 | Nov 30, 2018 | % Growth | ||||||
Net Sales by Global Business Unit | |||||||||
Vascular Interventions & Therapies | $ | 31,150 | $ | 30,976 | 0.6% | ||||
Vascular Access | 22,784 | 23,723 | (4.0)% | ||||||
Oncology | 16,069 | 15,286 | 5.1% | ||||||
Total | $ | 70,003 | $ | 69,985 | 0.0% | ||||
Net Sales by Geography | |||||||||
United States | $ | 55,555 | $ | 56,300 | (1.3)% | ||||
International | 14,448 | 13,685 | 5.6% | ||||||
Total | $ | 70,003 | $ | 69,985 | 0.0% |
• | Total Vascular Interventions & Therapies sales increased $0.2 million primarily attributable to strong performance in the AngioVac business which grew $1.7 million and in Core Peripheral products which grew $0.4 million year over year. The Company continues to see strong case volumes in AngioVac, which increased 31% from the prior year due to increased adoption of the Company's unique technology and the launch of the next generation of the AngioVac product. These increases were partially offset by the termination of the Asclera distribution agreement, which contributed $1.7 million of revenue in the prior year. |
• | U.S. Vascular Interventions & Therapies sales increased $0.4 million due to increased case volume in AngioVac and increased Core Peripheral product sales which was partially offset by the termination of the Asclera distribution agreement, which contributed $1.7 million of revenue in the prior year. |
• | International Vascular Interventions & Therapies sales decreased $0.2 million. |
• | Total Vascular Access sales decreased $0.9 million due to decreases in PICCs and Ports partially offset by growth in the Dialysis business of $0.1 million. BioFlo product lines comprise 52% of overall Vascular Access sales compared to 50% a year ago. |
• | U.S. Vascular Access sales decreased by $1.5 million due to competitive pressures in the PICC product lines and lower Port sales. This was partially offset by growth in Dialysis products which continue to gain traction in the marketplace. |
• | International Vascular Access sales increased by $0.6 million as the Company continues to expand its global reach of its Vascular Access product offerings. |
• | Total Oncology sales increased $0.8 million year over year primarily due to increased NanoKnife capital sales of $1.9 million and $0.3 million in increased sales of balloons. This was partially offset by decreased sales of Radiofrequency Ablation and NanoKnife disposable sales. |
• | U.S. Oncology sales increased by $0.3 million, driven by NanoKnife capital sales of $1.6 million and balloons of $1.6 million. This was partially offset by a decrease in RadioFrequency Ablation and NanoKnife disposable sales. |
• | International Oncology sales increased by $0.5 million year over year as a result of increased NanoKnife capital sales of $0.9 million. This was partially offset by decreased NanoKnife disposable and RadioFrequency and Microwave Ablation product sales. |
Three months ended | |||||||||||
(in thousands) | Nov 30, 2019 | Nov 30, 2018 | % Change | ||||||||
Gross profit | $ | 41,544 | $ | 40,552 | 2.4 | % | |||||
Gross profit % of sales | 59.3 | % | 57.9 | % | |||||||
Research and development | $ | 7,764 | $ | 7,076 | 9.7 | % | |||||
% of sales | 11.1 | % | 10.1 | % | |||||||
Selling and marketing | $ | 20,113 | $ | 19,263 | 4.4 | % | |||||
% of sales | 28.7 | % | 27.5 | % | |||||||
General and administrative | $ | 10,994 | $ | 9,262 | 18.7 | % | |||||
% of sales | 15.7 | % | 13.2 | % |
• | Sales volume and mix driven by AngioVac and NanoKnife capital sales positively contributed $1.5 million year over year. |
• | Net productivity contributed $0.4 million of favorability driven by purchase price variances. |
• | Favorable freight expense contributed $0.3 million. |
• | Currency and pricing headwinds negatively impacted gross margin by $0.1 million year over year, primarily driven by pricing. |
• | The termination of the Asclera distribution agreement negatively impacted gross margin by $1.0 million. |
• | Compensation and benefits increased approximately $0.5 million due to increased variable compensation along with increased headcount as a result of the Eximo acquisition. |
• | Increased project spend contributed $0.3 million of additional expense. |
• | Compensation and benefits increase of approximately $0.8 million which is primarily attributed to increased variable compensation and increased commissions as a result of NanoKnife capital sales during the second quarter. |
• | Other sales and marketing expenses increased $0.2 million to support company-wide initiatives. |
• | Outside service fees decreased $0.2 million. |
• | Legal and professional fees relating to ongoing litigation that is within the normal course of business increased $1.5 million. |
• | Outside consultant spend increased $0.2 million. |
• | Compensation and benefits decreased approximately $0.2 million primarily as a result of the timing of fully vested stock based compensation awards and lower high cost benefit claims. |
Three months ended | ||||||||||||
(in thousands) | Nov 30, 2019 | Nov 30, 2018 | $ Change | |||||||||
Amortization of intangibles | $ | 4,530 | $ | 4,506 | $ | 24 | ||||||
Change in fair value of contingent consideration | $ | 145 | $ | 244 | $ | (99 | ) | |||||
Acquisition, restructuring and other items, net | $ | 1,421 | $ | 2,728 | $ | (1,307 | ) | |||||
Other expense | $ | 121 | $ | (1,250 | ) | $ | 1,371 |
• | Amortization expense remained consistent with the prior year. The addition of the Eximo product technology intangible asset increased intangible assets by $59.0 million and resulted in additional amortization expense of $0.7 million. This was partially offset by the write-off of the Merz intangible in the fourth quarter of fiscal year 2019 and other intangibles that became fully amortized. |
• | The change from the prior year is due to decreased amortization on the RadiaDyne contingent consideration as a result of the gain of $8.4 million that was recorded in the fourth quarter of fiscal year 2019 and the gain of $0.6 million that was recorded in the first quarter of fiscal year 2020. The Eximo contingent consideration was recorded for $14.9 million in the second quarter of fiscal year 2020. In addition, the final minimum payment of $1.2 million was paid for the Microsulis contingent consideration during the first quarter of fiscal 2020. |
• | M&A expense of $0.4 million was incurred in the second quarter of fiscal year 2020 compared to $1.5 million in the prior year. |
• | Legal expense, related to litigation that is outside of the normal course of business, of $0.7 million was recorded in the second quarter of fiscal year 2020 compared to $0.9 million in the prior year. |
• | In the second quarter of fiscal year 2020, the Company incurred $0.7 million of expense to move manufacturing facilities as a result of the sale of the Fluid Management business. |
• | As part of the sale of the Fluid Management business, the Company entered into a transition services agreement with Medline for certain legal, human resource, tax, accounting and information technology services from the Company for a period not to exceed 24 months. As a result of the transition services agreement, the Company invoiced Medline $0.6 million in the second quarter of fiscal year 2020. |
• | Other expenses of $0.3 million in the second quarter of fiscal year 2020 consists of expenses to move the manufacturing of BioSentry products and severance associated with the sale of the Fluid Management business. |
• | The decrease in other expenses from the prior year of $1.4 million is due to decreased interest expense of $1.2 million as the Credit Facility was paid down in full at the beginning of the first quarter of fiscal year 2020. In addition to the decrease in interest expense, interest income increased $0.1 million from the prior year as a result of increased cash due to proceeds from the sale of the Fluid Management business. |
Three months ended | ||||||||
(in thousands) | Nov 30, 2019 | Nov 30, 2018 | ||||||
Income tax expense (benefit) | $ | (0.6 | ) | $ | (0.2 | ) | ||
Effective tax rate including discrete items | 17.1 | % | 5.0 | % |
Six months ended | |||||||||
(in thousands) | Nov 30, 2019 | Nov 30, 2018 | % Growth | ||||||
Net Sales by Global Business Unit | |||||||||
Vascular Interventions & Therapies | $ | 60,063 | $ | 59,573 | 0.8% | ||||
Vascular Access | 45,943 | 47,513 | (3.3)% | ||||||
Oncology | 30,039 | 26,842 | 11.9% | ||||||
Total | $ | 136,045 | $ | 133,928 | 1.6% | ||||
Net Sales by Geography | |||||||||
United States | $ | 108,492 | $ | 107,796 | 0.6% | ||||
International | 27,553 | 26,132 | 5.4% | ||||||
Total | $ | 136,045 | $ | 133,928 | 1.6% |
• | Total Vascular Interventions & Therapies sales increased $0.5 million primarily attributable to strong performance in the AngioVac business which grew $2.7 million and in Core Peripheral products which grew $0.3 million year over year. The Company continues to see strong case volumes in AngioVac, which increased 33% from the prior year due to increased adoption of the Company's unique technology and the launch of the next generation of the AngioVac product. These increases were partially offset by the termination of the Asclera distribution agreement, which contributed $3.1 million of revenue in the prior year. |
• | U.S. Vascular Interventions & Therapies sales increased $0.2 million due to increased case volume in AngioVac and increased Core Peripheral product sales which were partially offset by the termination of the Asclera distribution agreement, which contributed $3.1 million of revenue in the prior year. |
• | International Vascular Interventions & Therapies sales increased $0.3 million due to increased volume in Angiographic catheters primarily in EMEA (Europe, the Middle East and Africa). |
• | Total Vascular Access sales decreased $1.6 million due to decreases in PICCs and Ports partially offset by growth in the Dialysis business of $0.6 million. BioFlo product lines comprise 51% of overall Vascular Access sales compared to 50% a year ago. |
• | U.S. Vascular Access sales decreased by $2.7 million due to competitive pressures in the PICC product lines and lower Port sales. This was partially offset by growth in Dialysis products which continue to gain traction in the marketplace. |
• | International Vascular Access sales increased by $1.1 million as the Company continues to expand its global reach of its Vascular Access product offerings. |
• | Total Oncology sales increased $3.2 million year over year primarily due to increased NanoKnife capital sales of $2.8 million along with $2.1 million and $0.9 million in increased sales of balloons and BioSentry products, respectively. This was partially offset by decreased sales of Radiofrequency Ablation and NanoKnife disposable sales. |
• | U.S. Oncology sales increased by $3.1 million, driven by NanoKnife capital sales of $1.3 million, balloon sales of $2.1 million and BioSentry sales of $0.8 million. This was partially offset by a decrease in RadioFrequency Ablation and NanoKnife disposable sales. |
• | International Oncology sales increased by $0.1 million year over year as a result of increased NanoKnife capital sales of $1.5 million. This was offset by decreased NanoKnife disposable and RadioFrequency and Microwave Ablation product sales. |
Six months ended | |||||||||||
(in thousands) | Nov 30, 2019 | Nov 30, 2018 | % Change | ||||||||
Gross profit | $ | 79,761 | $ | 76,505 | 4.3 | % | |||||
Gross profit % of sales | 58.6 | % | 57.1 | % | |||||||
Research and development | $ | 14,055 | $ | 14,450 | (2.7 | )% | |||||
% of sales | 10.3 | % | 10.8 | % | |||||||
Selling and marketing | $ | 39,493 | $ | 37,669 | 4.8 | % | |||||
% of sales | 29.0 | % | 28.1 | % | |||||||
General and administrative | $ | 19,448 | $ | 17,697 | 9.9 | % | |||||
% of sales | 14.3 | % | 13.2 | % |
• | Sales volume and mix driven by AngioVac and NanoKnife capital sales positively contributed $3.2 million year over year. |
• | Currency and pricing tailwinds positively impacted gross margin by $0.8 million year over year, primarily driven by pricing. |
• | The termination of the Asclera distribution agreement negatively impacted gross margin by $1.8 million. |
• | Compensation and benefits increased approximately $0.3 million due to increased variable compensation along with increased headcount as a result of the Eximo acquisition. |
• | Other R&D expenses, including facilities, samples and project initiatives timing resulted in a decrease of $0.8 million. |
• | Compensation and benefits increase of approximately $1.5 million which is primarily attributed to increased variable compensation and increased commissions as a result of NanoKnife capital sales during the second quarter. |
• | Other sales and marketing expenses increased $0.3 million to support company-wide initiatives. |
• | Outside service fees decreased $0.2 million. |
• | Legal and professional fees relating to ongoing litigation that is within the normal course of business increased $1.9 million. |
• | Outside consultant spend increased $0.3 million and other expenses increased $0.4 million. |
• | Compensation and benefits decreased approximately $0.8 million primarily as a result of the timing of fully vested stock based compensation awards and lower high cost benefit claims. |
Six months ended | ||||||||||||
(in thousands) | Nov 30, 2019 | Nov 30, 2018 | $ Change | |||||||||
Amortization of intangibles | $ | 8,398 | $ | 7,939 | $ | 459 | ||||||
Change in fair value of contingent consideration | $ | (303 | ) | $ | 256 | $ | (559 | ) | ||||
Acquisition, restructuring and other items, net | $ | 2,921 | $ | 7,150 | $ | (4,229 | ) | |||||
Other expense | $ | (442 | ) | $ | (2,053 | ) | $ | 1,611 |
• | The increase in amortization expense from the prior year is due to intangible asset additions as a result of the Eximo product technology intangible asset which increased intangible assets by $59.0 million and resulted in additional amortization expense of $0.7 million. This was partially offset by the write-off of the Merz intangible in the fourth quarter of fiscal year 2019 and other intangibles that became fully amortized. |
• | The change from the prior year is due to the gain of $0.6 million that was recorded on the technical milestones for the RadiaDyne contingent consideration in the first quarter of fiscal year 2020. The gain was partially offset by decreased amortization on the RadiaDyne contingent consideration as a result of the first quarter gain along with the $8.4 million gain that was recorded in the fourth quarter of fiscal year 2019. The Eximo contingent consideration was recorded for |
• | M&A expense of $0.6 million was incurred in fiscal year 2020 compared to $2.9 million in the prior year. |
• | Legal expense, related to litigation that is outside of the normal course of business, of $1.4 million was recorded in fiscal year 2020, which includes an offset of $0.4 million from the Biolitec bankruptcy settlement, compared to $3.7 million in the prior year. |
• | In fiscal year 2020, the Company incurred $1.5 million of expense to move manufacturing facilities as a result of the sale of the Fluid Management business. |
• | As part of the sale of the Fluid Management business, the Company entered into a transition services agreement with Medline for certain legal, human resource, tax, accounting and information technology services from the Company for a period not to exceed 24 months. As a result of the transition services agreement, the Company invoiced Medline $1.3 million in fiscal year 2020. |
• | Other expenses of $0.8 million in fiscal year 2020 consists of expenses to move the manufacturing of BioSentry products and severance associated with the sale of the Fluid Management business. |
• | The decrease in other expenses from the prior year of $1.6 million is due to decreased interest expense of $2.1 million as the Credit Facility was paid down in full at the beginning of the first quarter of fiscal year 2020. In addition to the decrease in interest expense, interest income increased $0.3 million from the prior year as a result of increased cash due to proceeds from the sale of the Fluid Management business. These increases are partially offset by the write-off of the deferred financing fees that were associated with the old Credit Facility of $0.6 million. Other expenses also include foreign currency fluctuations which increased by $0.3 million. |
Six months ended | ||||||||
(in thousands) | Nov 30, 2019 | Nov 30, 2018 | ||||||
Income tax expense (benefit) | $ | (0.7 | ) | $ | (1.4 | ) | ||
Effective tax rate including discrete items | 14.5 | % | 13.2 | % |
Six Months Ended | |||||||
(in thousands) | Nov 30, 2019 | Nov 30, 2018 | |||||
Cash used in: | |||||||
Operating activities | $ | (597 | ) | $ | 4,086 | ||
Investing activities | (50,124 | ) | (86,336 | ) | |||
Financing activities | (135,749 | ) | 51,254 | ||||
Effect of exchange rate changes on cash and cash equivalents | 76 | (280 | ) | ||||
Net change in cash and cash equivalents | $ | (186,394 | ) | $ | (31,276 | ) |
• | Net loss of $4.0 million plus the non-cash items, primarily driven by depreciation and amortization and stock based compensation, contributed to cash used in operations of $0.6 million. |
• | Working capital was negatively impacted by increased inventory on hand of $10.0 million and decreased accounts payable and accrued liabilities of $8.8 million. Accounts receivable had a favorable impact on working capital as a result of the sale of the Fluid Management business. |
• | Net income was driven by increased sales and increased gross profit. This was partially offset by higher operating expenses in research and development, selling and marketing and general administrative as well as costs related to our acquisition and restructuring activities. |
• | The Company continues to focus on optimizing its cash conversion cycle. In the second quarter of fiscal year 2019, working capital was negatively impacted by increased inventory on hand of $1.0 million. Additionally, even though days sales outstanding ("DSO") decreased by two days, receivables negatively impacted working capital by $3.1 million as a result of increased sales in the quarter. Also, the $12.5 million DOJ settlement payment that was made during the first quarter of fiscal year 2019 negatively impacted working capital from accounts payable and accrued liabilities. |
• | $4.0 million in fixed asset additions versus $1.4 million in the prior year. |
• | $45.8 million cash payment to acquire Eximo Medical Ltd. in the second quarter of fiscal year 2020 compared to a $37.0 million cash payment to acquire the BioSentry product from SSC and a $47.9 million cash payment to acquire RadiaDyne in fiscal year 2019. Refer to Note 2 to the financial statements. |
• | $132.5 million repayment of long-term debt in conjunction with the new Credit Agreement that was entered into at the beginning of the first quarter of fiscal year 2020. Refer to Note 8 of the financial statements. |
• | $55.0 million draw on the revolver in fiscal year 2019 as a result of the RadiaDyne acquisition described in Note 2 to the financial statements. |
• | $2.5 million repayment on the Term Loan in the prior year. This was consistent with the required amortization payment on the Term Loan. |
• | $1.3 million of outlays from stock option and ESPP activity versus $0.9 million in proceeds in the prior year. |
• | $1.2 million payment on earn-out liabilities in the current year compared to $2.1 million in the prior year. |
Item 3. | Quantitative and Qualitative Disclosures About Market Risk. |
Item 4. | Controls and Procedures. |
Item 1. | Legal Proceedings. |
Item 1A. | Risk Factors. |
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds. |
Issuer Purchases of Equity Securities | |||||||||||||
Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Programs (1) | Maximum Approximate Dollar Value of Shares that May Yet Be Purchased Under Plans or Programs (1) | ||||||||||
September 1, 2019 - September 30, 2019 | — | $ | — | — | $ | — | |||||||
October 1, 2019 - October 31, 2019 | — | $ | — | — | $ | — | |||||||
November 1, 2019 - November 30, 2019 | — | $ | — | — | $ | — | |||||||
Total | — | $ | — | — | — |
(1) | These amounts are not applicable as the Company currently does not have a share repurchase program in effect. |
Item 3. | Defaults on Senior Securities. |
Item 4. | Mine Safety Disclosures. |
Item 5. | Other Information. |
Item 6. | Exhibits. |
No. | Description | ||
10.1.8 | |||
21 | |||
31.1 | |||
31.2 | |||
32.1 | |||
32.2 | |||
101.INS | The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document | ||
101.SCH | XBRL Schema Document | ||
101.CAL | XBRL Calculation Linkbase Documents | ||
101.DEF | XBRL Taxonomy Extension Definition Linkbase Document | ||
101.LAB | XBRL Labels Linkbase Documents | ||
101.PRE | XBRL Presentation Linkbase Documents |
ANGIODYNAMICS, INC. | ||||
(Registrant) | ||||
Date: | January 8, 2020 | / S / JAMES C. CLEMMER | ||
James C. Clemmer, President, Chief Executive Officer (Principal Executive Officer) | ||||
Date: | January 8, 2020 | / S / STEPHEN A. TROWBRIDGE | ||
Stephen A. Trowbridge, Senior Vice President, General Counsel and Interim Chief Financial Officer (Interim Principal Financial and Accounting Officer) |
Year 1 Performance Shares | ||||||||
Worldwide Revenue (in millions) | Worldwide Adjusted EPS | |||||||
(50% of Year 1 Performance Shares) | (50% of Year 1 Performance Shares) | |||||||
Target (%) | Worldwide Revenue ($) | Revenue Payout Percentage (%) | Target (%) | Worldwide Adjusted EPS ($) | EPS Payout Percentage (%) | |||
103.00% | $ 292.5 | 200% | 115.00% | $ 0.30 | 200% | |||
102.40% | $ 290.8 | 180% | 112.00% | $ 0.29 | 180% | |||
101.80% | $ 289.1 | 160% | 109.00% | $ 0.28 | 160% | |||
101.20% | $ 287.4 | 140% | 106.00% | $ 0.28 | 140% | |||
100.60% | $ 285.7 | 120% | 103.00% | $ 0.27 | 120% | |||
100.00% | $ 284.0 | 100% | 100.00% | $ 0.26 | 100% | |||
99.00% | $ 281.2 | 80% | 97.00% | $ 0.25 | 80% | |||
98.00% | $ 278.3 | 60% | 94.00% | $ 0.24 | 60% | |||
97.00% | $ 275.5 | 40% | 91.00% | $ 0.24 | 40% | |||
96.00% | $ 272.6 | 20% | 88.00% | $ 0.23 | 20% | |||
95.00% | $ 269.8 | 0% | 85.00% | $ 0.22 | 0% |
Year 2 Performance Shares | ||||||||
Worldwide Revenue Growth | Worldwide Adjusted EPS | |||||||
(50% of Year 2 Performance Shares) | (50% of Year 2 Performance Shares) | |||||||
Target (%) | Worldwide Revenue Growth (%) | Revenue Payout Percentage (%) | Target (%) | Worldwide Adjusted EPS ($) | EPS Payout Percentage (%) | |||
150.00% | 9.0% | 200% | 116.00% | $ 0.58 | 200% | |||
140.00% | 8.4% | 180% | 112.80% | $ 0.56 | 180% | |||
130.00% | 7.8% | 160% | 109.60% | $ 0.55 | 160% | |||
120.00% | 7.2% | 140% | 106.40% | $ 0.53 | 140% | |||
110.00% | 6.6% | 120% | 103.20% | $ 0.52 | 120% | |||
100.00% | 6.0% | 100% | 100.00% | $ 0.50 | 100% | |||
90.00% | 5.4% | 80% | 96.80% | $ 0.48 | 80% | |||
80.00% | 4.8% | 60% | 93.60% | $ 0.47 | 60% | |||
70.00% | 4.2% | 40% | 90.40% | $ 0.45 | 40% | |||
60.00% | 3.6% | 20% | 87.20% | $ 0.44 | 20% | |||
50.00% | 3.0% | 0% | 84.00% | $ 0.42 | 0% |
Year 3 Performance Shares | ||||||||
Worldwide Revenue Growth | Worldwide Adjusted EPS | |||||||
(50% of Year 3 Performance Shares) | (50% of Year 3 Performance Shares) | |||||||
Target (%) | Worldwide Revenue Growth (%) | Revenue Payout Percentage (%) | Target (%) | Worldwide Adjusted EPS ($) | EPS Payout Percentage (%) | |||
150.00% | 10.5% | 200% | 116.00% | $ 0.87 | 200% | |||
140.00% | 9.8% | 180% | 112.80% | $ 0.85 | 180% | |||
130.00% | 9.1% | 160% | 109.60% | $ 0.82 | 160% | |||
120.00% | 8.4% | 140% | 106.40% | $ 0.80 | 140% | |||
110.00% | 7.7% | 120% | 103.20% | $ 0.77 | 120% | |||
100.00% | 7% | 100% | 100.00% | $ 0.75 | 100% | |||
90.00% | 6.3% | 80% | 96.80% | $ 0.73 | 80% | |||
80.00% | 5.6% | 60% | 93.60% | $ 0.70 | 60% | |||
70.00% | 4.9% | 40% | 90.40% | $ 0.68 | 40% | |||
60.00% | 4.2% | 20% | 87.20% | $ 0.65 | 20% | |||
50.00% | 3.5% | 0% | 85.00% | $ 0.64 | 0% |
Relative TSR | TSR Multiplier | |
75th Percentile or Above | 1.2 | |
50th Percentile | 1.0 | |
25th Percentile or Below | 0.8 |
(a) | “Change in Control” shall mean that any of the following events has occurred: |
(b) | “Disability” means disability as determined by the Board in its sole discretion. |
(c) | The “Peer Group” means the Company, together with the group of companies set forth on Schedule A hereto: |
(d) | “Relative TSR” means “relative total shareholder return,” expressed as a percentile, and calculated as follows: |
(1) | “TSR,” or “total shareholder return,” for each member of the Peer Group shall be calculated using the following formula: |
(2) | Following the calculation of the TSR for the Performance Period for the Company and each other company in the Peer Group, the Company and the other companies in the Peer Group will be ranked, in order of maximum to minimum, according to their respective TSR for the Performance Period. |
(3) | After this ranking, the Company’s Relative TSR, expressed as a percentile, shall be determined by the following formula: |
(e) | “Retirement” means retirement as determined by the Board in its sole discretion. |
(f) | “Worldwide Revenue” means for any particular Performance Year: revenue as publicly reported by the Company for that year and as reviewed by the Board’s Audit Committee and Compensation Committee. |
(g) | “Worldwide Revenue Growth” means for any particular Performance Year: the following quotient (expressed as a percentage): (A) the excess, if any, of Worldwide Revenue for that year minus Worldwide Revenue for the immediately preceding Performance Year, divided by (B) Worldwide Revenue for the immediately preceding Performance Year. |
Becton, Dickinson and Company | Stryker Corporation |
Boston Scientific Corporation | Intuitive Surgical, Inc. |
Edwards Lifesciences Corporation | Varian Medical Systems, Inc. |
STERIS plc | ResMed Inc. |
Teleflex Incorporated | Integra LifeSciences Holdings Corporation |
DexCom, Inc. | NuVasive, Inc. |
Invacare Corporation | Cantel Medical Corp. |
CONMED Corporation | Masimo Corporation |
Wright Medical Group N.V. | Abiomed, Inc. |
Insulet Corporation | Natus Medical Incorporated |
Accuray Incorporated | CryoLife, Inc. |
AtriCure, Inc. | Abbott Laboratories |
Medtronic plc | Danaher Corporation |
Baxter International Inc. | Zimmer Biomet Holdings, Inc. |
Hologic, Inc. | IDEXX Laboratories, Inc. |
Envista Holdings Corporation | LivaNova PLC |
Integer Holdings Corporation | Globus Medical, Inc. |
Varex Imaging Corporation | Orthofix Medical Inc. |
Penumbra, Inc. | Inogen, Inc. |
Nevro Corp. | Tandem Diabetes Care, Inc. |
NovoCure Limited | Glaukos Corporation |
Cardiovascular Systems, Inc. |
Subsidiary | State of Incorporation or Organization | |
Vortex Medical | Delaware | |
NM Holding Company, Inc. | Delaware | |
Navilyst Medical Holdings, Inc. | Delaware | |
Navilyst Medical, Inc. | Delaware | |
AngioDynamics UK Limited | United Kingdom | |
AngioDynamics Netherlands B. V. | Netherlands | |
RITA Medical Systems, LLC | Delaware | |
AngioDynamics France, SARL | France | |
AngioDynamics Canada Inc. | British Columbia | |
AngioDynamics Medical Brasil Participacoes Ltda. | Sao Paulo | |
RadiaDyne LLC | Texas | |
Eximo Medical, Ltd. | Israel | |
AngioDynamics VA LLC | Delaware |
1. | I have reviewed this quarterly report on Form 10-Q of AngioDynamics, Inc.; | |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; | |
4. | The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: | |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |
(c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |
(d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and | |
5. | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): | |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and | |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
1. | I have reviewed this quarterly report on Form 10-Q of AngioDynamics, Inc.; | |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; | |
4. | The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: | |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |
(c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |
(d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and | |
5. | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): | |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and | |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
1. | the quarterly report on Form 10-Q of the Company for the fiscal quarter ended November 30, 2019 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and | |
2. | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
/ S / JAMES C. CLEMMER | |
James C. Clemmer, President, Chief Executive Officer |
1. | the quarterly report on Form 10-Q of the Company for the fiscal quarter ended November 30, 2019 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and | |
2. | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
/ S / STEPHEN A. TROWBRIDGE | |
Stephen A. Trowbridge, Senior Vice President, General Counsel and Interim Chief Financial Officer |
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end
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end
)"8&P,AZ
M!3>*44FSILV;#HD9 (!&XHT8.(,*'3I1&1H -RJ.),JT:=!) ,0HLPB5J#)B
MF8A!<\K5Y%&2%Y?BW.BR+-BN:'V*Q7ACIDUE+6.0)'8#P-2T>!VVA%DR$P"^
M*HFY)&8P:M[# UN>Q:C,+DV_;@VB28HXKQ@#A#,"!C"IY%V!C2D[G 2T
Acquisition, Restructuring and Other Items, Net (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nov. 30, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring and Related Activities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restructuring and Related Costs | For the three and six months ended November 30, 2019 and 2018 acquisition, restructuring and other items, net consisted of:
(1) Legal expenses related to litigation that is outside the normal course of business. (2) Mergers and acquisitions expenses related to investment banking, legal and due diligence. (3) Transition services agreement that was entered into as a result of the sale of the Fluid Management business. (4) Divestiture expenses incurred to transition manufacturing from Glens Falls, NY to Queensbury, NY. |
Earnings Per Share (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nov. 30, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding | The following table reconciles basic to diluted weighted-average shares outstanding for the three and six months ended November 30, 2019 and 2018 (in thousands):
|
Revenue from Contracts with Customers (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nov. 30, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenue from Contract with Customer [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disaggregation of Revenue | The following tables summarize net product revenue by Global Business Unit ("GBU") and geography for the three and six months ended November 30, 2019 and 2018:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contract Balances with Customers | The following table presents changes in the Company’s receivables, contract assets and contract liabilities with customers:
|
Consolidated Financial Statements |
6 Months Ended |
---|---|
Nov. 30, 2019 | |
Accounting Policies [Abstract] | |
Consolidated Financial Statements | CONSOLIDATED FINANCIAL STATEMENTS The Consolidated Balance Sheet as of November 30, 2019, the Consolidated Statements of Operations and the Consolidated Statements of Comprehensive Income (Loss) for the three and six months ended November 30, 2019 and 2018, the Consolidated Statements of Stockholders’ Equity for the three months ended November 30, 2019 and 2018 and the Consolidated Statements of Cash Flows for the six months ended November 30, 2019 and 2018 have been prepared by us and are unaudited. The Consolidated Balance Sheet as of May 31, 2019 was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to state fairly the financial position, changes in stockholders’ equity and comprehensive income, results of operations and cash flows as of and for the period ended November 30, 2019 (and for all periods presented) have been made. The unaudited interim consolidated financial statements for the three and six months ended November 30, 2019 and 2018 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, collectively, the “Company”. All intercompany balances and transactions have been eliminated. On May 31, 2019, the Company completed the sale of the Fluid Management business and all of the assets used primarily in connection with the Fluid Management business (Note 3). As the disposal of this business represents a strategic shift with a major effect on the Company's operations, for all periods presented in our Consolidated Statements of Operations and Comprehensive Loss, all sales, costs, expenses, gains and income taxes attributable to Fluid Management have been reported under the captions, “Income from Discontinued Operations, Net of Income Tax.” Cash flows used in or provided by Fluid Management have been reported in the Consolidated Statements of Cash Flows under operating and investing activities.
|
Goodwill and Intangible Assets |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nov. 30, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets | GOODWILL AND INTANGIBLE ASSETS Intangible assets other than goodwill are amortized over their estimated useful lives on either a straight-line basis or proportionately to the benefit being realized. Useful lives range from two to eighteen years. The Company periodically reviews the estimated useful lives of its intangible assets and reviews such assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets or asset groups may not be recoverable. If an intangible asset or asset group is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset. Goodwill is not amortized, but rather, is tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. The Company's annual testing for impairment of goodwill was completed as of December 31, 2018. The Company operates as a single operating segment with one reporting unit and consequently evaluates goodwill for impairment based on an evaluation of the fair value of the Company as a whole. The Company determines the fair value of the reporting unit based on the market valuation approach and concluded that it was not more-likely-than-not that the fair value of the Company's reporting unit was less than its carrying value. Even though the Company determined that there was no goodwill impairment as of December 31, 2018, the future occurrence of a potential indicator of impairment, such as a significant adverse change in legal, regulatory, business or economic conditions or a more-likely-than-not expectation that the reporting unit or a significant portion of the reporting unit will be sold or disposed of, would require an interim assessment for the reporting unit prior to the next required annual assessment as of December 31, 2019. The changes in the carrying amount of goodwill for the six months ended November 30, 2019 were as follows:
Intangible assets consisted of the following:
Amortization expense for the three months ended November 30, 2019 and 2018 was $4.5 million and $4.5 million, respectively. Amortization expense for the six months ended November 30, 2019 and 2018 was $8.4 million and $7.9 million, respectively. Expected future amortization expense related to the intangible assets is as follows:
|
Share-Based Compensation |
6 Months Ended |
---|---|
Nov. 30, 2019 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Share-Based Compensation | SHARE-BASED COMPENSATION The Company has two stock-based compensation plans that provide for the issuance of up to approximately 11.3 million shares of common stock. The 2004 Stock and Incentive Award Plan (the "2004 Plan") provides for the grant of incentive options to the Company's employees and for the grant of non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other incentive awards to the Company's employees, directors and other service providers. The Company also has an employee stock purchase plan. For the three months ended November 30, 2019 and 2018, share-based compensation expense was $2.2 million and $2.6 million, respectively. For the six months ended November 30, 2019 and 2018, share-based compensation expense was $4.2 million and $4.7 million, respectively. During the six months ended November 30, 2019 and 2018, the Company granted stock options and restricted stock units under the 2004 Plan to certain employees and members of the Board of Directors. Stock option awards are valued using the Black-Scholes option-pricing model and then amortized on a straight-line basis over the requisite service period of the award. Restricted stock unit awards are valued based on the closing trading value of the Company's shares on the date of grant and then amortized on a straight-line basis over the requisite service period of the award. During the six months ended November 30, 2019 and 2018, the Company granted performance share units under the 2004 Plan to certain employees. The awards may be earned by achieving relative performance levels over the three year requisite service period. The performance criteria are based on achieving certain performance targets and the total shareholder return ("TSR") of the Company's common stock relative to the TSR of the common stock of a pre-defined industry peer-group. The fair value of these awards are based on the closing trading value of the Company's shares on the date of grant and use a Monte Carlo simulation model. |
Goodwill and Intangible Assets - Goodwill Rollforward (Details) $ in Thousands |
6 Months Ended |
---|---|
Nov. 30, 2019
USD ($)
| |
Goodwill [Roll Forward] | |
Goodwill balance at May 31, 2019 | $ 347,666 |
Additions for Eximo acquisition (Note 2) | 12,428 |
Goodwill balance at November 30, 2019 | $ 360,094 |
Segment and Geographic Information - Summary of Net Sales by Product Category (Detail) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Nov. 30, 2019 |
Nov. 30, 2018 |
Nov. 30, 2019 |
Nov. 30, 2018 |
|
Segment Reporting Information [Line Items] | ||||
Net sales | $ 70,003 | $ 69,985 | $ 136,045 | $ 133,928 |
Vascular Interventions & Therapies | ||||
Segment Reporting Information [Line Items] | ||||
Net sales | 31,150 | 30,976 | 60,063 | 59,573 |
Vascular Access | ||||
Segment Reporting Information [Line Items] | ||||
Net sales | 22,784 | 23,723 | 45,943 | 47,513 |
Oncology | ||||
Segment Reporting Information [Line Items] | ||||
Net sales | $ 16,069 | $ 15,286 | $ 30,039 | $ 26,842 |
Leases - Liability Maturity Schedule (Details) $ in Thousands |
Nov. 30, 2019
USD ($)
|
---|---|
Leases [Abstract] | |
Remainder of 2020 | $ 736 |
2021 | 1,251 |
2022 | 1,118 |
2023 | 1,138 |
2024 | 576 |
2025 and thereafter | 0 |
Total lease payments | 4,819 |
Less: Imputed Interest | 235 |
Total lease obligations | 4,584 |
Less: Current portion of lease obligations | 1,393 |
Long-term lease obligations | $ 3,191 |
Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands |
Nov. 30, 2019 |
May 31, 2019 |
---|---|---|
Inventory Disclosure [Abstract] | ||
Raw materials | $ 19,092 | $ 16,045 |
Work in process | 10,541 | 6,786 |
Finished goods | 20,606 | 17,240 |
Inventories | $ 50,239 | $ 40,071 |
Recently Issued Accounting Pronouncements (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nov. 30, 2019 | |||||||||||||||||||||||||||||||||||||||||||||
Accounting Changes and Error Corrections [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||
Recently Issued Accounting Pronouncements | The following table provides a description of recent accounting pronouncements that may have a material effect on the Company's consolidated financial statements:
|
Leases Leases |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nov. 30, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases | LEASES Adoption of ASU No. 2016-02, Leases (Topic 842) On June 1, 2019, the Company adopted ASU No. 2016-02 using the modified retrospective approach. This ASU increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. Comparative periods prior to adoption have not been retrospectively adjusted. The Company elected the three practical expedients that permit an entity to a) not reassess whether expired or existing contracts contain leases, b) not reassess lease classification for existing or expired leases, and c) not consider whether previously capitalized initial direct costs would be appropriate under the new standard. Further, the Company has elected to not recognize leases with terms of 12 months or less on the balance sheet, and elected to account for lease and non-lease components as a single component for certain classes of assets. The adoption of this standard resulted in the recording of an additional lease asset and lease liability of approximately $5.6 million. The standard did not have a material impact on the Company's Consolidated Statement of Operations, Stockholders Equity or Cash Flows. Leases The Company determines if an arrangement is a lease at inception of the contract. The Company has operating leases for buildings, primarily for office space, R&D, manufacturing and warehousing. Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Many of the lease agreements contain renewal or termination clauses that are factored into the determination of the lease term if it is reasonably certain that these options would be exercised. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The following table presents supplemental balance sheet information related to our leases:
The interest rate implicit in lease agreements is typically not readily determinable, and as such the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The incremental borrowing rate is defined as the interest the Company would pay to borrow on a collateralized basis, considering factors such as length of lease term. The following table presents the weighted average remaining lease term and discount rate:
The following table presents the maturities of the lease liabilities:
During the three and six months ended November 30, 2019, the Company recognized $0.9 million and $1.5 million of operating lease expense, respectively, which includes immaterial short-term leases. As of November 30, 2019, the expenses on the Consolidated Statement of Operations were classified as follows:
In addition to the total lease obligations presented in the table above, the Company has a 7-year building operating lease with undiscounted payment obligations of $6.5 million and a 2-year building operating lease with undiscounted payment obligations of $0.4 million that are expected to commence during fiscal year 2020. Future annual payments under non-cancelable operating leases in the aggregate at May 31, 2019, are summarized as follows:
The following table presents supplemental cash flow and other information related to our leases for the six months ended:
|
Recently Issued Accounting Pronouncements |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nov. 30, 2019 | |||||||||||||||||||||||||||||||||||||||||||||
Accounting Changes and Error Corrections [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||
Recently Issued Accounting Pronouncements | RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS The following table provides a description of recent accounting pronouncements that may have a material effect on the Company's consolidated financial statements:
|
Divestitures (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nov. 30, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discontinued Operations and Disposal Groups [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Results of Discontinued Operations | The following table summarizes the financial results of our discontinued operations:
Total operating and investing cash flows of discontinued operations for the six months ended November 30, 2018 is comprised of the following, which excludes the effect of income taxes:
|
Fair Value - Fair Value Measurements Using Significant Unobservable Inputs (Detail) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended |
---|---|---|
Nov. 30, 2019 |
Nov. 30, 2019 |
|
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Financial liabilities, begining balance | $ 11,830 | $ 13,486 |
Contingent consideration liability recorded as the result of the acquisitions (Note 2) | 14,900 | 14,900 |
Change in present value of contingent consideration | 145 | (303) |
Contingent consideration payments | (1,208) | |
Financial liabilities, ending balance | $ 26,875 | $ 26,875 |
Leases - Supplemental Balance Sheet Information (Details) $ in Thousands |
Nov. 30, 2019
USD ($)
|
---|---|
Leases [Abstract] | |
Operating lease ROU asset | $ 4,603 |
Less: Current portion of lease obligations | 1,393 |
Long-term lease obligations | 3,191 |
Total lease obligations | $ 4,584 |
Weighted average remaining term (in years) | 3 years 7 months 6 days |
Weighted average discount rate (percent) | 4.50% |
Inventories - Narrative (Detail) - USD ($) $ in Millions |
6 Months Ended | |
---|---|---|
Nov. 30, 2019 |
May 31, 2019 |
|
Inventory [Line Items] | ||
Inventory valuation reserves | $ 4.0 | $ 4.2 |
Inventory write-down | 0.7 | |
Acculis Inventory | ||
Inventory [Line Items] | ||
Inventory valuation reserves | $ 0.3 | $ 0.4 |
"7%! 7":@/B7WJ[)]05\^A[@32\GES49K?XC]Y
MB(E67+O/+8 N4VT0 YO(B.M%/&X1C-L\2;C!4OTRRO!DZ[.Z_X5KW5?&=M5R
M9PBI(P-750=@A/>K@)Q_%:/$9KV(464ZTVHF*%!-^;1\H\24KE@DF=(+@=%Y
MK O_RU>0#Z1^8 /^O&E$3X]UGW1:T&K@QG"14*PHP2
M12.8Y4Q OF/5=7UN <*D S"TJ"5 ^#G?!@_5OXSW-[T*W9[?8I$*_31MW)J6Z@WYSPFA1 4@#)STE"
ME%@I"502J-;R-XN(9-2OV*1J-\>7P2ZSK8NJYOB^$
MI$JE4=]VH$LQ$,CG/E1:8\*ZRSHJ*7UG^+8]?%O78GBSTP:%)*V5[
MS>J%V_%TS)(?K90;,\.8&6V!HM7XTL1X#\ZSWDO..QJ&.J2%7LV3,<'\@[)W
M-G%?C5XY +WRYIRWN:6]YVSUMGN'^ZICC'MUP.[5GH&1.2]K(,NPQINSQIZA
MADFD/TA#^LT!JE'==;1FUI$FTK>*>P\%$ T\[<+EVR^>.&XE^>:FVFI;^?O%
M4F:!M[M!>GC&SM$
ZA9W;YT[W(52.A^*DKYUHB(RE
MDU!1U@DZWQ7CGGV-D^_J)6&0*4CJJ89LH#=;@ZS3"^^B>'A0ZFJ@^)X .L;8
M$CXKN'U7=X3YCS!;YT3SHIH.XR49E4G8:!]\>7'?M1]XD30REH9FQEH#0EO'
MCW&2JV_^.8BTJE<:OC@&GA9U-;(%JA_K9.)A,8BI ;#_''F1'#%_?'\(BP3V
M62;YT/D)_CR<#^7<%/S1ZP3]_H1)RMQS&XXZJ"E]C'M2UIG2VECUW@(MWGKXL+6>;H!RRX7#
MU%L?_A3""\L=4U0#9+G?:,/Z//C4I. ([E%>I]G<<#5V]-[XN_'7( ^3S:R(
M(ZF.OD_PK35E8U@0X*EECL%@;!H%?=!D3"FOG39$W0??:EJO ^;VIJLHZ"$L
M6VU,=ME'[3#R2%6X,%B*C%OMM;>&4FTTYDAH8R'U4$C-GX>\NM0&BJ-I-0S*;FAD ,IC-!^LR?M850CQ+ G^4'Z5#96*R9_
ML9780U6: 42>0AU4I,22*AM4J!684 >80H)N'M8\C$;$D/:01*W&7HO2#J/#
M.+D*-W_=RZY&>51ZP5^,N4I7\
M874F[S669=M$IL<,JB?,7P@(KNQ?S[RW5"& %864:N, H8@ZY1'#:J.4XVZH
MJL\4QCW ZNSETTUKN,'Z[]WX:S&>3S;[J70C#OLD=M=\5Z$Y)@XB*3RGD&.%
M"$+6>^>T0=YL9A5L8'=MLO>:JP=Z !PD7>]XX)Q